Respiratory diseases are leading causes of death and disability globally, with about 65 million people suffering from COPD, and 334 million from asthma, the most common chronic disease. Each year, tens of millions of people develop and can die from from respiratory infections such as pneumonia and TB. Systemic inflammation may induce and exacerbate local inflammatory diseases in the lungs, and local inflammation can in turn cause systemic inflammation. There is increasing evidence of the coexistence of systemic and local inflammation in patients suffering from asthma, COPD, and other lung diseases, and the co-morbidity of two or more local inflammatory diseases often occurs. For example, rheumatoid arthritis frequently occurs together with, and promotes the development of, pulmonary hypertension. This co-morbidity significantly impacts quality of life, and can result in death for those affected. Current treatment options for lung disease are neither effective, nor condition-specific; there is a desperate need for novel therapeutics in the field. Additionally, the molecular and physiological significance of most major lung diseases is not well understood, which further impedes development of new treatments, especially in the case of coexistent lung diseases with other inflammatory diseases. Great progress has been made in recent years in many areas of the field, particularly in understanding the molecular geneses, regulatory mechanisms, signalling pathways, and cellular processes within lung disease, as well as basic and clinical technology, drug discovery, diagnoses, treatment options, and predictive prognoses. This is the first text to aggregate these developments. In two comprehensive volumes, experts from all over the world present state-of-the-art advances in the study of lung inflammation in health and disease. Contributing authors cover well-known as well as emerging topics in basic, translational, and clinical research, with the aim of providing researchers, clinicians, professionals, and students with new perspectives and concepts. The editors hope these books will also help to direct future research in lung disease and other inflammatory diseases, and result in the development of novel therapeutics.

Lung diseases are leading causes of death and disability globally, with about 65 million people suffering from COPD, and 334 million from asthma. Each year, tens of millions of people develop and can die from lung infections such as pneumonia and TB. Systemic inflammation may induce and exacerbate local inflammatory diseases in the lungs, and local inflammation can in turn cause systemic inflammation. There is increasing evidence of the coexistence of systemic and local inflammation in patients suffering from asthma, COPD, and other lung diseases, and the co-morbidity of two or more local inflammatory diseases often occurs. For example, rheumatoid arthritis frequently occurs together with, and promotes the development of, pulmonary hypertension. This co-morbidity significantly impacts quality of life, and can result in death for some patients. Current treatment options for lung disease are neither always effective, nor condition-specific; there is a desperate need for novel therapeutics in the field. Additionally, the molecular and physiological significance of most major lung diseases is not well understood, which further impedes development of new treatments, especially in the case of coexistent lung diseases with other inflammatory diseases. Great progress has been made in recent years in many areas of the field, particularly in understanding the molecular geneses, regulatory mechanisms, signalling pathways, and cellular processes within lung disease, as well as basic and clinical technology, drug discovery, diagnoses, treatment options, and predictive prognoses. This is the first text to aggregate these developments. In two comprehensive volumes, experts from all over the world present state-of-the-art advances in the study of lung inflammation in health and disease. Contributing authors cover well-known as well as emerging topics in basic, translational, and clinical research, with the aim of providing researchers, clinicians, professionals, and students with new perspectives and concepts. The editors hope these books will also help to direct future research in lung disease and other inflammatory diseases, and result in the development of novel therapeutics.

Lung diseases are leading causes of death and disability globally, with about 65 million people suffering from COPD, and 334 million from asthma. Each year, tens of millions of people develop and can die from lung infections such as pneumonia and TB. Systemic inflammation may induce and exacerbate local inflammatory diseases in the lungs, and local inflammation can in turn cause systemic inflammation. There is increasing evidence of the coexistence of systemic and local inflammation in patients suffering from asthma, COPD, and other lung diseases, and the co-morbidity of two or more local inflammatory diseases often occurs. For example, rheumatoid arthritis frequently occurs together with, and promotes the development of, pulmonary hypertension. This co-morbidity significantly impacts quality of life, and can result in death for some patients. Current treatment options for lung disease are neither always effective, nor condition-specific; there is a desperate need for novel therapeutics in the field. Additionally, the molecular and physiological significance of most major lung diseases is not well understood, which further impedes development of new treatments, especially in the case of coexistent lung diseases with other inflammatory diseases. Great progress has been made in recent years in many areas of the field, particularly in understanding the molecular geneses, regulatory mechanisms, signalling pathways, and cellular processes within lung disease, as well as basic and clinical technology, drug discovery, diagnoses, treatment options, and predictive prognoses. This is the first text to aggregate these developments. In two comprehensive volumes, experts from all over the world present state-of-the-art advances in the study of lung inflammation in health and disease. Contributing authors cover well-known as well as emerging topics in basic, translational, and clinical research, with the aim of providing researchers, clinicians, professionals, and students with new perspectives and concepts. The editors hope these books will also help to direct future research in lung disease and other inflammatory diseases, and result in the development of novel therapeutics.

Degeneration of nerve cells that control cognitive, speech, and language processes leading to linguistic impairments at various levels, from verbal utterances to individual speech sounds, could indicate signs of neurological, cognitive and psychiatric disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), dementias, depression, autism spectrum disorder, schizophrenia, etc. Currently, these disorders are diagnosed using specific clinical diagnostic criteria and neuropsychological examinations. However, speech-based biomarkers could potentially offer many advantages over current clinical standards. In addition to being objective and naturalistic, they can also be collected remotely with minimal instruction and time requirements. Furthermore, Machine Learning algorithms developed to build automated diagnostic models using linguistic features extracted from speech could aid diagnosis of patients with probable diseases from a group of normal population. To ensure that speech-based biomarkers are providing accurate measurement and can serve as effective clinical tools for detecting and monitoring disease, speech features extracted and analyzed must be systematically and rigorously evaluated. Different machine learning architectures trained to classify different types of disordered speech must also be rigorously tested and systematically compared.

Pulmonary Biology in Health and Disease was conceived as a companion to a handful of expensive, multivolume textbooks. This is part of the promising trend to publish shorter textbooks on the subjects of lung biology and remodeling. Whoever is familiar with human biology and the far-reaching consequences of the genome and postgenome revolutions is apt to concede that the centerpiece in remodeling lies in the ?eld of m- ecular cardiobiology. The ?eld of molecular cardiobiology includes the syndrome of chronic heart failure as well as ischemic cardioprotection. By analogy, the centerpiece in pulmonobiology is chronic asthma. Key topics in the present volume include s- naling mechanisms regulating the endothelium and smooth muscle cells,in?ammatory cells, mediators, airway surface liquid, and pharmacological therapy that focuses on how in?amed airways are altered. Written primarily for predoctoral and postdoctoral graduates in the basic medical sciences, the medical student and postdoctoral physician, graduates in the allied s- ences, nurses, pulmonologists, and physicians in critical care medicine, this book p- vides many of the fundamentals of contemporary pulmonology. It is divided into several parts devoted to the control of respiration, arterial chemoreceptors,muscles of ventilation, pulmonary physiology, and gas exchange in health, exercise, and disease. Special emphasis is placed on emphysema and its pathobiology, acute lung injury, asthma and inhaled toxicants. Because the ?eld is always evolving, each chapter includes recommended readings that lead the reader to sources of additional information, such as the review on remodeling of the blood gas barrier by West and Mathieu-Costello.

Interstitial Lung Disease, Fourth Edition is a complete publication of interstitial lung diseases and includes clinical, pathologic, radiologic, and physiologic evaluation of the patient with ILD. It provides a basic pathobiology and a complete description of individual disease entities. The book covers a wide array of disorders - sarcoidosis, asbestosis, hypersensitivity pneumonitis, drug-induced lung disease, connective tissue disease, and pulmonary vasculitis, to name but a few. This new edition also features an examination of future potential therapies for interstitial lung disease. Interstitial Lung Disease is divided into three sections. The Clinical Approach section provides the basis for recognizing the key features that allow a specific diagnosis to be achieved. The section dedicated to Basic Mechanisms emphasizes the many advances in genetics and cellular and molecular biology that have greatly expanded our understanding of the biological processes involved in the pathogenesis of the interstitial lung diseases. The third section titled Clinical Entities describes the clinical manifestations, radiologic patterns, histopathological features, and management of the specific process

Biotechnology in Healthcare presents up-to-date knowledge on the emerging field of biotechnology as applied to the healthcare industry. Biotechnology has revolutionized healthcare in the last two decades by developing and introducing novel diagnostics, therapeutics, and preventive measures; whether it is noncommunicable or communicable disease, primary or secondary care, or public health, it has shown its immense potential to provide a solution to the healthcare providers, physicians, and allied health care professionals.The second volume, Applications and Initiatives, contains 19 chapters focused on the applications of biotechnology related to public healthcare, hospital management, oncology, neurodegenerative and infectious diseases, regenerative medicine, IVF, clinical trials, precision food, FMGCs, PPCPs, pharmaceuticals, and smart technologies to monitor pandemic. Further, this volume also presents government initiatives and entrepreneurship challenges in healthcare biotechnology sector.This is a valuable resource for students, biotechnologists, bioinformaticians, clinicians, and members of biomedical and healthcare fields who need to understand more about the promising developments of the emerging field of biotechnology in healthcare. - Describes various applications of novel biotechnology approaches in healthcare - Presents applications of biotechnology in primary and secondary healthcare and in public health - Discusses government initiatives, challenges and opportunities, and entrepreneurship development in the area of healthcare biotechnology